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Antibodies accumulate nonspecifically in infectious foci due to the 
locally increased vascular permeability. This study describes a 
method of infection imaging in which " mTc-DTPA (diethylenetri- 
aminepentaacetic acid) is trapped at the target by a previously 
administered anti-DTPA monoclonal antibody, DTInl. Methods: 
Rats with Staphylococcus aureus-infected calf muscle were injected 
intravenously with DTInl. Two to 24 hr after the DTInl injection, 
99mTc-DTPA was injected intravenously. In separate experiments, 
excess DTInl was cleared from the circulation 2 hr after injection 
with bovine serum albumin (BSA)-DTPA-In, galactosylated BSA- 
DTPA-ln, goat antimouse IgG or avidin. Additionally, the effect of 
DTInl dose on 99mTc-DTPA abscess uptake was determined in a 
three-step protocol. The distribution of the radiolabels was studied 
by y counting of dissected tissue and gamma camera imaging. 
Results: Priming with DTInl resulted in specific retention of 99nTc- 
DTPA in the abscess. Such " mTc-DTPA abscess uptake was not 
dependent on the interval between the DTInl and the 99mTc-DTPA 
injection: Optimal " mTc-DTPA abscess uptake was already 
achieved within a 2-hr time span between the DTInl and DTPA 
injections. However, relatively high " mTc-DTPA background was 
observed due to slowly clearing DTInl -99mTc-DTPA complexes. 
Background reduction with various agents had a prominent effect 
on DTInl as weil as " mTc-DTPA biodistribution. The best reduction 
was obtained using BSA-DTPA-ln. Optimai 99mTc-DTPA abscess 
uptake in the three-step protocol was obtained at higher DTInl 
doses (>100 /xg). Conclusion: Infectious foci in a rat model can be 
imaged earlier with extremely low background levels after priming 
with DTInl, followed by BSA-DTPA-ln and imaging with 99mTc- 
DTPA, as compared with directly labeled IgG.
Key Words: technetium-99m~DTPA; monoclonal antibody priming; 
infection imaging; pretargeting protocols .
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cintigraphic imaging of focal infection is currently per­
formed with various agents, such as 67Ga-citrate, radiolabeled 
leukocytes or 111 In-labeled human IgG (1,2). Large proteins 
such as IgG and human serum albumin localize nonspecifically 
in infectious and inflammatory foci due to the locally enhanced
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vascular permeability (3,4). Although labeled IgG is a conve­
nient radiopharmaceutical, its relatively slow blood clearance, 
which causes persistently high background activity, interferes 
with the early diagnosis of infection and inflammation (5).
Reduction of background activity may be accomplished by 
pretargeting protocols. In these methods, the infectious focus is 
pretargeted and the radionuclide is administered afterwards as a 
low molecular weight ligand. The small ligand is rapidly 
excreted when not targeted to the infectious focus. Streptavidin 
and biotin have been used in such multistep approaches (6-8). 
Rusckowski et al. pretargeted mice with Escherichia coli 
infection with cold streptavidin and injected n Tn-biotin 3 hr 
later (8). Higher abscess-to-background ratios were obtained 
compared with 111 In-streptavidin or 1]1In-IgG. Similar results 
were observed in tumor pretargeting studies using antichelate 
antibodies and radiometal labeled chelates (9-12).
In this study, wc investigated a multistep strategy for rapid 
infection imaging using an anti-DTPA (diethylenetriaminepen- 
taacetic acid) monoclonal antibody (MAb) as the pretargeting 
agent and " mTc-DTPA as the targeting radiopharmaceutical.
MATERIALS AND METHODS
Radiopharmaceuticals
Technetium-99m-IgG. Human nonspecific IgG in kit form 
(Technescan-HIG; Mallinckrodt Medical B.V., Petten, The 
Netherlands) was labeled with 750 MBq " mTc eluate according 
to the manufacturer’s instructions.
Monoclonal Antibodies. The production of anti-DTPA MAb 
DTInl (IgG2a), reacting with DTPA loaded with different 
metals, has been described (13). The affinity constant for 
" mTc-DTPA was approximately 0,2 nM~l, which is similar to 
that for u lIn-DTPA (13). The IgG2a switch variant of MAb 
G250 (14) was used as a non-DTPA binding-control antibody. 
DTInl and G250 were labeled with 125I (Amersham Interna­
tional, Buckinghamshire, U.K.) using the Iodogen method (15).
Biotinylated DTInl. DTInl was conjugated with NHS-LC- 
biotin (Pierce, Rockford, IL). Briefly, 0.8 mg DTInl and 740 
jag NHS-LC-biotin in 50 mM sodium phosphate (pH 7.5) were 
incubated for 16 hr at 4°C. Thereafter, unreacted biotin was 
removed by PD10 (Pharmacia LKB Technology, Uppsala, 
Sweden) chromatography. Each DTInl molecule contained 18
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biotins as determined by the method of Green (16). In vivo, the 
" mTc-DTPA binding capacity of biotinylated DTInl and 
DTInl were similar.
Bovine Serum Albumin (BSA)-DTPA-In. BSA (Sigma Chem­
ical Co., St. Louis, MO) was conjugated with the cyclic 
anhydride of DTPA (Sigma) in a 1 :20 molar ratio as described 
by Hnatowich et al. (17). After PD10 chromatography to 
remove unreacted DTPA, excess InCl3 (Merck, Darmstadt, 
Germany) was added. Five DTPA molecules were conjugated 
per BSA molecule as determined by the ITLC method described 
by Hnatowich et aL (77).
Galactosyl at ed BSA-DTPA-ln. BSA-DTPA-ln was galacto- 
sylated essentially as described by Marshall et al. (18). To 36.5 
mg dry activated galactose 10 mg BSA-DTPA-ln (5 mg/ml in 
25 mM sodium borate, pFI 8.5) were added and allowed to react 
for 2 hr. PD1Ö chromatography was used to remove unreacted 
galactose. Thirty-two galactose molecules were conjugated per 
BSA-DTPA-ln molecule as determined by the method of 
Dubois et al. (19).
Technetium~99m-DTPA. A kit containing 1 mg DTPA, 0.6 
mg calcium nitrate and 0.05 mg stannous sulfate (pH 5.0) was 
radiolabeled with a fresh " mTc eluate.
Animal Studies
Animal Model. A Staphylococcus aureus calf muscle abscess 
was induced in young, male Wistar rats according to the method 
of Oyen et al. (3). Experiments were initiated 24 hr after the
S. aureus inoculation. All radiopharmaceuticals were intrave­
nously injected.
Bioclistribution Studies. Rats were injected intraperitoneally with 
a phénobarbital overdose, bled by cardiac puncture and killed. 
Tissues were dissected and weighed. The activity in tissues and 
injection standards was measured in a shielded well scintillation y  
counter and expressed as the percentage of injected dose per gram 
(%ID/g). From these data abscess-to-blood ratios (ABR) and 
abscess-to-contralateral muscle ratios (AMR) were calculated. In 
all experiments, groups of five rats were used.
Immunoscintigraphy. Groups of four rats were anesthesized 
(nitrous oxide/oxygen/halothane) and placed prone on a gamma 
camera (Orbiter, Siemens, Hoffman Estates, IL) equipped with a 
low-energy, parallel hole collimator. Images (400,000 counts per 
image) were obtained up to 2 hr postinjection (p.i.) and stored in a 
256 X 256 matrix. The images were analyzed by drawing regions 
of interest over the whole animal, the abscess and the contralateral 
calf muscle (background). The abscess-to-background ratios and 
abscess-to-whole body ratios were calculated.
Targeting o f Infections with Tech n eti um - 99m -IgG. Each rat 
was injected with 25 jag " mTc-IgG (750 MBq/mg). The rats 
were killed, and the biodistribution was determined 4, 8 and 24 
hr after injection.
Two-Phase Targeting of Infections. Each rat was injected with 
100 jag DTInl (3MBq/mg) or 100 /xg 125I-G250 (4 MBq/mg). 
Twenty-four hours later, the rats received 7.5 MBq " mTc-DTPA 
(0.2 jag), and 2 hr later biodistribution studies were performed.
Optimization o f Time Between DTInl ancl DTPA Injection. 
DTInl (100 jug labeled with 300 kBq 125I) was injected into 
each rat. Technetium-99m-DTPA (0.2 jag labeled with 7.5 
MBq) was injected at 2, 6 or 24 hi'. Radiolabel bio distributions 
were determined 2 hr p.i.
Three-Step Targeting of Infections. Ten rats were injected with 
100 jag DTInl. Two hours later, 5 of the 10 rats received 500 jag 
BSA-DTPA-ln. All rats received 15 MBq " mTc-DTPA (1.4 jag) 
30 min later, and images were obtained up to 120 min p.i. As 
control, a third group of rats received 7.5 MBq " mTc-DTPA (0,7 
jag) only. Images were obtained up to 20 min p.i.
The three-phase targeting protocol was also studied in a 
biodistribution experiment. Ten rats received 300 jag DTInl 
labeled with 370 kBq 125I. After 2 hr, 5 of the 10 rats received 
650 jag BSA-DTPA-ln. Rats in both groups received 4 MBq 
" mTc-DTPA (4 jag) 2.5 hr after the first injection, and 
biodistribution was determined 1 hr later.
Comparison o f Background-Reducing Agents. Four back­
ground-reducing agents were studied in the three-step protocol: 
BSA-DTPA-ln, galactosylated BSA-DTPA-ln (gal-BSA- 
DTPA-In), goat antimouse IgG (GAM-IgG; rat serum ab­
sorbed; Southern Biotechnology Associates Inc., Birmingham, 
AL) and avidin (Sigma). Rats were injected with 30 jag DTInl 
(labeled with 2 MBq 125I) or 30 jag biotinylated DTInl (labeled 
with 3 MBq 125I). Two hours later, a 10-fold molar excess of 
background-reducing agents was injected [assuming an anti­
body blood level of 4%ID/g and a total blood volume of 12 ml
(3)], Thirty minutes later, 4 MBq " mTc-DTPA (3.5 jag) were 
injected. The biodistribution was determined 30 min p.i.
Antibody Dose Optimization, Increasing amounts of ,25I- 
DTInl (10-900 jag per rat, labeled with 370 kBq 125I) were 
injected. Two hours later, BSA-DTPA-ln was injected into each 
rat at a calculated 10-fold molar excess. Thirty minutes later, 
each rat was injected with 4 MBq " mTc-DTPA (3.3 jag), and 
9gmTc-DTPA biodistribution was determined 1 hr p.i.
Statistical Analysis. All mean values are ± s.d. Statistical 
analysis was performed using one-way analysis of variance, 
with Bonferroni post-test correction for multiple comparisons,
RESULTS 
Two-Phase Targeting of Infections
Priming rats with DTInl for 24 hr had a profound effect on 
the " mTc-DTPA biodistribution (Fig. 1). Whereas almost no 
differences in the biodistribution between DTInl and G250 
were observed (data not shown), " mTc-DTPA activity was 
significantly higher in DTInl primed rats in all examined 
tissues with the exception of the kidneys (p <  0.0001).
Optimization of the Time Between DTInl 
and DTPA Injection
In Table 1, biodistribution of 125I-DTInl is shown 4, 8 and 26 
hr after injection. The %ID/g 125I-DTInl in the blood decreased 
with time. More importantly, the 125I-DTInl uptake in the 
abscess was similar up to 26 hr after injection. Neither the ABR 
nor the AMR of ,25I-DTInl improved with time.
The %ID/g " mTc-DTPA in blood decreased significantly 
with increasing intervals between the DTInl and DTPA injec­
tions (Table 1). The " mTc-DTPA uptake in other organs and in 
the abscess was not significantly affected by the interval 
between the DTInl and " mTc-DTPA injections. The ABR 
slightly improved from 0.27 at the 6-hr interval to 0.46 at the 
24-hr interval between the DTInl and " mTc-DTPA injections. 
No significant differences were observed in " mTc-DTPA 
AMRs. Optimal abscess uptake of " mTc-DTPA had been 
achieved during the 2 hr between the DTInl and DTPA 
injections. However, due to the high DTInl blood levels, 
" mTc-DTPA background levels remained high.
To clarify the role of the two-step strategy, biodistribution 
studies with " mTc-IgG were performed (Table 2). High back­
ground levels were also observed with " mTc-IgG. The AMR was 
significantly higher using " mTc-IgG, but no significant differences 
were observed in ABRs when " mTc-IgG 4 hr post- infection was 
compared with " mTc-DTPA in the two-phase protocol with a 2-hr 
timespan. Early imaging of infectious foci, in terms of ABRs, was 
not improved using this two-step protocol.
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FIGURE 1. Biodistribution of 99fTTc-DTPA 
after DTInl (solid bars) or G250 (hatched 
bars) priming. Twenty-four hours after an­
tibody injection, rats were injected with 
" mTc-DTPA, and 99mTc-DTPA biodistri­
bution was determined 2 hr later.
Three-Step Targeting of Infectious Foci
The effect of BSA-DTPA-ln on " mTc-DTPA abscess uptake 
and whole-body distribution was studied scintigraphically. Ad­
ministration of BSA-DTPA-ln resulted in a marked change in 
whole-body distribution of " mTc-DTPA (Fig. 2). With the two- 
and three-step protocols, the abscesses were clearly visualized. 
However, a notable decrease of circulating " mTc-DTPA was 
observed in BSA-DTPA-In-treated rats. With the three-step 
protocol, the abscess-to-background ratio increased to 14.8 ± 
3.1 2 hr after t)9mTc-DTPA injection. Due to the rapid excretion 
of the nontargeted 99mTc-DTPA, the abscess uptake as a 
percentage of residual activity increased up to 16.3% 2 hr after 
tt;mTc-DTPA injection. In contrast, rats receiving " mTc-DTPA 
only showed minimal abscess uptake (2.3% ± 0.3% of whole- 
body activity 20 min p.i.), and the abscess-to-background ratio 
did not exceed 2.
In the biodistribution experiment, striking differences be­
tween two- and three-step protocols were observed. A decrease
in MmTc-DTPA uptake was seen in blood (17-fold reduction), 
abscess (1.9-fold decrease) and other organs of rats treated with 
BSA-DTPA-ln (Fig. 3). More importantly, the " mTc-DTPA
ABR was significantly higher in three-phase protocol rats 
(1.97 ± 0.42 versus 0.22 ± 0.03; p <  0,001), whereas the AMR 
was not different. The %ID/g l25I-DTInl in blood, kidneys and 
lungs significantly decreased, whereas a significant increase 
was seen in the liver and spleen, indicating DTInl-BSA- 
DTPA-ln complexation and subsequent metabolization (Fig. 3 
inset). The amount of 125I-DTInl in the abscess was similar in 
both pretargeting protocols.
The three-step approach resulted in significant improvement 
of the ABR for " mTc-IgG 4 hr p.i. (1.97 ± 0.42 versus 0.35 ± 
0.05; p <  0.0001).
Comparison of Different Background-Reducing Agents
All agents effectively reduced the %ID/g " mTc-DTPA in the 
blood (Table 3). BSA-DTPA-ln had the most prominent effect
Tc-DTPA blood levels, with a 5.6-fold reduction com­
pared with the two-step protocol. Only slightly (but signifi­
cantly) decreased " mTc-DTPA abscess uptake was observed 
after injection of BSA-DTPA-ln or gal-BSA-DTPA-In. Lower 
" mTc-DTPA levels were observed in the liver and spleen 












Optimization of Time Between DTInl and DTPA Injection
Biodistribution of 125i-DTIn1 
(%!D/g or ratio; mean values ±  s.d.)
4 hr p.L
3.17 ±0.17 
0,10 ± 0.02 
0.83 ±  0.22 
0.67 ±  0,05 
0.82 ±  0.08 
0.48 ±  0.04 
0.26 ±  0.06 
8.96 ±  3.07
8 hr p.i.
2.45 ±0.15 
0.08 ±  0,01 
0.88 ±  0.32 
0.55 ±  0.13 
0.77 ±0.12 
0,47 ± 0.08 
0.36 ±  0.15 
10.26 ±2.10
26 hr p.i.
1.50 ±  0.21 
0.10 ± 0.01 
0.66 ± 0.10 
0.28 ±  0.03 
0.43 ± 0.06 
0.23 ±  0.04 
0,44 ±  0.07 
6.44 ±0.17
Biodistribution of " mTc-DTPA 2 hr p.i. 
at different intervals between DTInl and DTPA injections
(%lD/g or ratio; mean values ± s.d.)
2-hr interval
1.72 ± 0.04 
0.06 ± 0.01 
0.49 ±0.12 
0.39 ± 0.03 
1.04 ± 0.09 




1.42 ±  0,08 
0.08 ±  0.03 
0.48 ±0,10 
0.28 ±0.12 
1.08 ±  0.23 





0.08 ± 0.01 
0.44 ± 0.08 
0.22 ± 0.03 
0.88 ± 0.07 
0.16 ±0,02 
0.46 ± 0.06 
5.83 ±0.16
p.i. = postinjection.
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FIGURE 3. Comparison between the 
three-phase protocol (DTInl, BSA-DTPA- 
ln, DTPA; solid bars) and the two-phase 
protocol (DTInl, DTPA; hatched bars). 
Biodistribution of 99mTc-DTPA 1 hr after 
injection is shown. Biodistribution of 125l- 
DT!n1 3.5 hr after injection is shown in the 
inset.
The best reduction o f  " mTc-DTPA background was obtained 
with BSA-DTPA-ln; A 5.6-fold reduction o f  " mTc-DTPA 
blood level was achieved with a concomittant 3 .5-fold increase 
in the ABR. The use o f  a background-reducing agent that can 
block the DTInl antigen-binding site does not hamper the 
targeting o f  infectious foci with c9niTc-DTPA. Therefore, the 
behavior o f  BSA-DTPA-ln in these studies was superior to the 
other background-reducing agents.
Goodwin et al. used a similar background reduction approach 
to image tumors in mice (P). A three-step protocol was designed 
using an anti-BLEDTA IV antibody, a human transferrin- 
chelate conjugate and m In~BLEDTA IV. Due to the back­
ground reduction step, decreased l l l In-BLEDTA IV tumor
uptake and increased tumor-to-blood ratios were observed 
similar to our observations. In their study of mice with E. coli 
infection, Rusckowski et al. demonstrated that infection imag­
ing could be improved, in terms of ABR and AMR, using 
streptavidin pretargeting and radiolabeled biotin (8 ).
With our three-step strategy, rapid imaging of infectious foci 
was achieved: high abscess-to-background ratios were obtained 
within 30 min p.i. o f DTPA and 3 hr after the first injection. The 
three-phase targeting protocol may potentially improve the 
infection imaging at earlier times after tracer injection in 
humans. A limitation to this approach might be the development 
o f  a HAMA response after administration of DTInl. For clinical 
studies, a humanized DTInl antibody is preferable. Immuno-
Organ
TABLE 3


















3.81 ± 0.27 
0.08 ± 0.004 
1.00 ± 0.21 
0.68 ± 0.10 















Biodistribution of 125t-DTIn1 (%ID/g; mean value ± s.d.)
3.77 ±  0.32 
0.08 ±  0.01 
0.93 ± 0.22 
1.07 ± 0.12’ 
1.25 ±0.11 ’
1.90 ±0.10* 
0.07 ± 0.005 
0.54 ± 0.14* 
3.28 ±0.19* 
0.46 ± 0.03*
0.57 ± 0.06* 
0.11 ± 0.01* 
0.56 ± 0.05* 
2.67 ± 0.08* 
2.63 ± 0.42*
Biodistribution of 99mTc-DTPA (%!D/g or ratio; mean value
0.40 ±0.04* 1.16 ±0.08*
0.07 ± 0.01 0.08 ± 0.01
0.36 ± 0.09* 0.39 ± 0.09*
0.15 ± 0.02* 0.33 ±0.03*
0.11 ± 0.01f 0.22 ±0.01
0.90 ± 0.26* 0.34 ± 0.08
5.17 ±  0.86* 5.34 ±1.57
± s.d.)
0.51 ± 0.04* 
0.08 ± 0.01 
0.47 ± 0.05 
0.50 ± 0.04 
1.78 ± 0.29* 
0.92 ± 0.09* 
6.06 ± 0.75
0.82 ±  0.09* 
0.11 ± 0.01* 
0.59 ±  0.07* 
1.99 ±0.19* 
2.71 ±  0.54*
0.72 ±  0.09* 
0.08 ± 0.01 
0.48 ± 0.08 
0.76 ± 0.06* 
1.34 ±0.30* 
0.67 ± 0.07* 
5.89 ± 1.01
*Significant difference as compared with two-phase protocol (i.e., DTInl) at p <  0.001.
Significant difference as compared with two-phase protocol at p <  0.01.
^Significant difference as compared with two-phase protocol at p <  0.001.
No significant differences were observed between DTInl and biotinylated DTInl; only DTInl results are shown.
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FIGURE 4. Biodistribution of 99mTc-DTPA after priming with increasing DTInl doses and chasing with a 10-fold molar excess of BSA-DTPA-ln. Two hours 
after DTInl injection, BSA-DTPA-ln was injected, and DTPA was injected 30 min later. Biodistribution data were obtained 1 hr after DTPA injection.
genicity of the background-reducing agent can be minimized by 
the use of a  human serum protein as a carrier. The immunoge- 
nicity o f  avidin ( 6) might hamper the use o f  the avidin-biotin 
system for infection imaging in humans, especially since a 
human equivalent of avidin is not available.
A  potential drawback to the three-step method is the rela­
tively large D TInl protein dose needed in humans. The use o f  
multivalent DTPA might facilitate the use of lower DTInl 
doses in view of the higher affinity of antichelate antibodies for 
multivalent chelates compared to monovalent chelates (77).
CONCLUSION
Three-phase targeting o f  infectious foci results in early 
imaging with low background levels as compared with two- 
phase targeting protocols or directly labeled nonspecific IgG.
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